1. Activation of EphB4 by ephrinB2‐Fc prevents aberrant angiogenesis
Activation of EphB4 by ephrinB2‐Fc prevents aberrant angiogenesis A–FA high VEGF dose was delivered to limb muscles of mice either by genetically modified myoblasts (V‐high, A–C) or as fibrin‐bound recombinant protein (fibrin‐High V, D–F), and animals were treated intraperitoneally with ephrinB2‐Fc or control Fc recombinant protein. Immunostaining (A, D) of frozen sections for endothelium (CD31, red), pericytes (NG2, green), smooth muscle cells (α‐SMA, cyan), and nuclei (DAPI, blue) showed that, with both delivery platforms, ephrinB2‐Fc treatment prevented the induction of aberrant vascular structure by high VEGF and yielded only normal capillary networks. *lumens of aberrant structures in (D); scale bar = 25 μm. Quantification (B, C, E, and F) of vessel diameters showed a consistent and significant decrease in vessel sizes after treatment with ephrinB2‐Fc. Results are shown as diameter distributions (B, E) and mean ± SEM (C, F). Red arrows and numbers indicate the fraction of vessel diameters > 10 μm. n = 4 mice; *P < 0.05 (Mann–Whitney test).
Elena Groppa et al. EMBO Rep. 2018;embr
© as stated in the article, figure or figure legend